OMERS ADMINISTRATION Corp Has $2.23 Million Stock Holdings in Natera, Inc. $NTRA

OMERS ADMINISTRATION Corp increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 28.2% in the 1st quarter, Holdings Channel.com reports. The fund owned 11,126 shares of the medical research company’s stock after buying an additional 2,445 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Natera were worth $2,225,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Horizon Investments LLC grew its stake in Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its stake in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. raised its stake in shares of Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares in the last quarter. Finally, First Horizon Corp lifted its holdings in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after buying an additional 51 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on NTRA. The Goldman Sachs Group initiated coverage on Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. UBS Group set a $260.00 price objective on Natera in a research report on Wednesday, June 24th. William Blair began coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. boosted their price target on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Sanford C. Bernstein began coverage on Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Insider Activity

In other Natera news, Director Herm Rosenman sold 16,530 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 164,101 shares of company stock worth $36,644,427. 5.05% of the stock is owned by company insiders.

Natera Price Performance

Shares of NTRA opened at $252.22 on Wednesday. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04. The company has a market capitalization of $36.12 billion, a P/E ratio of -154.74 and a beta of 1.51. The business’s 50 day simple moving average is $243.18 and its 200-day simple moving average is $221.55.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.